MarketCap
Facebook
X
TelegramGeschäftsbericht 2023
hinzugefügt 16.04.2024
Advaxis Operativer Cashflow 2011-2026 | ADXS
Operativer Cashflow Jährlich Advaxis
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29.5 M | -34.5 M | -15.4 M | -21.9 M | -36.1 M | -62.1 M | -76.8 M | - | - | - | -8.71 M | -4.57 M | -8.94 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -4.57 M | -76.8 M | -29.9 M |
Operativer Cashflow Vierteljährlich Advaxis
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -6.74 M | -4.14 M | - | - | -9.98 M | -2.79 M | - | -8.9 M | - | -7.71 M | -18.7 M | -13.4 M | - | -11.9 M | -27 M | -19.8 M | - | -12.7 M | -48.9 M | -30.8 M | - | - | -58.7 M | -33.7 M | - | - | -31.1 M | -16.8 M | - | - | - | - | - | - | - | - | - | -1.14 M | - | - | - | -2.13 M | -3.94 M | -2.79 M | - | -2.17 M | -7.4 M | -3.18 M | -2.17 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -1.14 M | -58.7 M | -14.9 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.55 | -0.28 % | $ 1.06 B |  Canada |
 |
Adagene
ADAG
|
-29.7 M | $ 3.91 | -2.01 % | $ 220 M |  China |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
AC Immune SA
ACIU
|
-65.7 M | $ 3.32 | 6.07 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
ADC Therapeutics SA
ADCT
|
-233 M | $ 4.11 | -2.61 % | $ 105 M | Schweiz |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 0.79 | 0.04 % | $ 4.31 M | China |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
argenx SE
ARGX
|
-607 M | $ 706.03 | 0.39 % | $ 25 B |  Niderland |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.34 | -7.48 % | $ 8.04 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 228.06 | -1.28 % | $ 5 B |  Danmark |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 3.43 | -4.19 % | $ 7.46 B |  Israel |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-1.79 M | $ 14.51 | 1.04 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 6.39 | -3.62 % | $ 175 M | Israel |
 |
BioNTech SE
BNTX
|
890 M | $ 94.86 | 4.77 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 8.28 | 2.86 % | $ 1.34 B | Britain |
 |
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | USA |
 |
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-33.1 M | $ 1.14 | 2.7 % | $ 34.3 M | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.51 | - | $ 385 M | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-57.3 M | - | - | $ 521 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-132 M | $ 6.13 | 1.32 % | $ 500 M | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Equillium
EQ
|
-21.8 M | $ 2.15 | -7.33 % | $ 74.7 M | USA |